- Home
- EQBK vs ABUS Comparison
EQBK vs ABUS Comparison
Compare EQBK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQBK | ABUS |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.8M | 888.5M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | EQBK | ABUS |
|---|---|---|
| Price | $46.10 | $3.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $50.50 | $5.00 |
| AVG Volume (30 Days) | 94.6K | ★ 2.0M |
| Earning Date | 01-21-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $199,739,000.00 | $14,606,000.00 |
| Revenue This Year | $76.83 | $125.30 |
| Revenue Next Year | $4.61 | N/A |
| P/E Ratio | $37.50 | ★ N/A |
| Revenue Growth | N/A | ★ 116.64 |
| 52 Week Low | $34.11 | $2.71 |
| 52 Week High | $50.07 | $5.10 |
Technical Indicators
Market Signals| Indicator | EQBK | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 42.56 |
| Support Level | $46.07 | $3.62 |
| Resistance Level | $48.25 | $4.26 |
| Average True Range (ATR) | 1.32 | 0.31 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 31.80 | 40.45 |
Price Performance
Historical ComparisonAbout EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.